UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ý
Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement | |||||||||||||||||||
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |||||||||||||||||||
| ¨ | Definitive Proxy Statement | |||||||||||||||||||
| ý | Definitive Additional Materials | |||||||||||||||||||
| ¨ | Soliciting Material Pursuant to § 240.14a-12 | |||||||||||||||||||
| Revance Therapeutics, Inc. | ||||||||||||||||||||
| (Name of Registrant as Specified in its Charter) | ||||||||||||||||||||
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | ||||||||||||||||||||
| Payment of Filing Fee (Check all boxes that apply): | ||||||||||||||||||||
| ý | No fee required. | |||||||||||||||||||
| ¨ | Fee paid previously with preliminary materials. | |||||||||||||||||||
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 | |||||||||||||||||||
